SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Spring Bank Pharmaceuticals, Inc. (NasdaqGS – SBPH)

BALA CYNWYD – July 30, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Spring Bank Pharmaceuticals, Inc. (“Spring Bank” or the “Company”) (NasdaqGS – SBPH) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the share exchange agreement with F-star Therapeutics, Limited (“F-star”), a privately-held clinical-stage biopharmaceutical company. Under the terms of the share exchange agreement, Spring Bank shareholders will be significantly diluted, holding only approximately 38.8% of the combined company, and receiving two Contingent Value Rights (“CVR”) with respect to certain Spring Bank programs.

The investigation concerns whether the Spring Bank Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.

If you own shares of Spring Bank stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or call toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.